Novartis' Zometa cleared in Switzerland
Novartis has been granted marketing authorization from the Swissregulatory authorities for Zometa (zoledronic acid), its new-generation intravenous bisphosphonate for the treatment of tumor-induced hypercalcemia. This is the second approval of Zometa, after Canada, and Novartis has also received an approvable letter for the product in the USA (Marketletters passim).
Novartis said Zometa would be launched in Switzerland in January 2001 and added that the drug is also under regulatory review in the European Union and Canada. Analysts have predicted that Zometa could achieve sales of more than $150 million at peak.
Improvements over Aredia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze